eptacog alfa at a glance
Medicine class
Recombinant activated coagulation factor VII
Main role
Treating bleeding or supporting haemostasis during surgery in specified bleeding disorders
Specialist oversight
Treatment is initiated by clinicians experienced in haemophilia or bleeding disorders
What is eptacog alfa used for?
Licensed uses represented by the selected products include treating bleeding and preventing bleeding during surgery or invasive procedures in specified groups.
Congenital haemophilia with significant inhibitors to factor VIII or IX
Congenital haemophilia where a strong inhibitor response to factor VIII or IX is expected
Acquired haemophilia
Congenital factor VII deficiency
Glanzmann’s thrombasthenia when platelet transfusion is ineffective or platelets are not readily available
Severe postpartum haemorrhage when uterotonic treatment has not achieved haemostasis
How does eptacog alfa work?
At an injury, eptacog alfa promotes activation of factors IX and X and increases local thrombin formation, helping platelets and fibrin form a stable clot. It can also activate factor X directly on activated platelets, helping bypass factor VIII or IX inhibitors.
eptacog alfa preparations and strengths
Injection
Route: Parenteral
Strengths: 2 mg
How to take eptacog alfa
Eptacog alfa is injected into a vein. Mix the powder with the supplied solvent using aseptic technique, gently swirl rather than shake, and inspect the solution before use.
Use at home only if authorised and after training from the specialist team.
Do not use a solution that is discoloured or contains visible particles.
Do not mix it with infusion solutions or administer it as an intravenous drip.
Record and report each use as instructed by the specialist team.
eptacog alfa side effects
Common or expected effects
- Fever, rash, itching or hives may occur, although these are classed as uncommon overall.
- Nausea, headache and injection-site reactions have been reported.
- In congenital factor VII deficiency, antibodies against factor VII or eptacog alfa are classed as common and may reduce response.
Get urgent medical advice
- Severe allergic or anaphylactic reaction
- Venous blood clots, including deep-vein thrombosis or pulmonary embolism
- Arterial blood clots, including heart attack or stroke
- Disseminated intravascular coagulation
- Reduced or absent haemostatic response
eptacog alfa in pregnancy
As a precaution, use during pregnancy is preferably avoided unless a specialist considers it necessary. Available exposure data are limited, and pregnancy, delivery and severe haemorrhage can add to thromboembolic risk.
eptacog alfa while breastfeeding
It is unknown whether eptacog alfa passes into human milk. The benefits of breastfeeding and the clinical need for treatment should be weighed together.
eptacog alfa interactions
The specialist team should review all haemostatic treatments because combining clotting products may alter safety or response.
Prothrombin complex concentrates, activated or non-activated
Concurrent use should be avoided because the interaction and thrombotic risk are uncertain.
Recombinant factor XIII
The combination is not recommended because non-clinical evidence suggests exaggerated coagulation effects.
Antifibrinolytics, including tranexamic acid or aminocaproic acid
Combined use may be considered clinically, but experience is limited and specialist oversight is required.
Common questions about eptacog alfa
Answers are fully visible for fast scanning and source review.
What is eptacog alfa used for?
It treats or prevents bleeding in specified bleeding disorders and is also licensed for severe postpartum haemorrhage when uterotonics have not achieved haemostasis.
Why is eptacog alfa used when haemophilia inhibitors are present?
It promotes clotting through activated factor VII and can bypass the blocked factor VIII- or IX-dependent pathway.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.